Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228180 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL15725461 | 0.83 | HDAC6 (0.83) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL15725471 | 0.81 | HDAC6 (0.83) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL15725412 | 0.81 | HDAC6 (0.84) | HDAC6 | |
| SCHEMBL15725455 | 0.78 | HDAC6 (0.85) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL15725473 | 0.76 | HDAC6 (0.85) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL10050271 | 0.74 | HDAC6 (0.81) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL24653262 | 0.74 | HDAC1 (0.75) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL20684933 | 0.74 | HDAC1 (0.75) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL15725449 | 0.74 | HDAC6 (0.75) | HDAC6HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142117-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142117-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.